Valeant, Biovail win investor OK for deal; Pfizer lambastes PLoS for 'undisclosed' conflicts;

 @FiercePharma: As Avandia dust settles, observers draw conclusions. Item | Follow @FiercePharma

> Valeant Pharmaceuticals and Biovail said their shareholders approved Biovail's $3.2 billion buyout of Valeant; the vote came as Biovail's founder and a pair of California state lawmakers raised objections to the deal. News

> Pfizer accused the medical journal PLoS Medicine of failing to fully disclose conflicts of interest related to a recent article taking issue with ghostwriting practices at Wyeth, bought by Pfizer last year. Report

> Centocor Ortho Biotech asked FDA to approve its anti-inflammatory drug Simponi as a stand-alone treatment for patients with moderate-to-severe rheumatoid arthritis. Story

> Indonesia's antitrust agency, KPPU, said it has found Pfizer, four of its units and a local firm guilty of breaching monopoly regulations on their anti-hypertensive products. Story

> AstraZeneca won U.K. approval for Seroquel XL as an add-on treatment for major depression in patients who haven't fully responded to antidepressant treatment. Item

> Trimeris will pay Novartis just over $2.4 million as part of a patent dispute settlement with Novartis over the HIV drug Fuzeon. Article

> Pharmaceutical services stocks may rally 30 percent over the next year as investors anticipate a surge in generic drugs coming to market. Report

> Sun Pharmaceutical Industries received FDA tentative approval to sell a copy of Sanofi-Aventis' Rilutek tablets, used for the treatment of amyotrophic lateral sclerosis. Item

Biotech News

 @FierceBiotech: AZ's zibotentan flunks late-stage prostate cancer trial. Article | Follow @FierceBiotech

 @JohnCFierce:The only brake on cancer drug pricing right now seems to be competition. Absent that, the sky's the limit.  | Follow @JohnCFierce

> Quark Pharma plots $20M IPO. News

> Palatin cuts half its workforce, discovery R&D. Item

> Sanofi buys VaxDesign for $60M. Report

> TetraLogic pushes Series C to $37M. Article

Biotech Research News

> Alzheimer's may prevent brain cancers. News

> Researchers excited by fresh signs SIRT1 can treat Alzheimer's. Story

> U.S. budgets $1.9B to back new drugs and vaccines. Article

> Stem cell enterprises promise to slash cost of drug development. Report

> Investigators herald new approach to next-gen cancer drugs. News

> Optogenetics experiment uses light to control muscles. Item

Manufacturing News

> Similac recall list grows by one. Item

> Catalent enhanced packaging requires content discretion. Story

> Lufthansa, Envirotainer unveil cold chain containers. Article

> Avastin fake causes eye infections in China. Report

> Drug/vial lamellae drive Amgen, J&J anemia-drug recalls. News

And Finally... Nestlé is challenging the global drugs industry with plans to invest $510 million over the next decade on a standalone health science business to tackle obesity and chronic disease. Report